Ja. Dumot et al., PRETREATMENT WITH METHYLPREDNISOLONE TO PREVENT ERCP-INDUCED PANCREATITIS - A RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED CLINICAL-TRIAL, The American journal of gastroenterology, 93(1), 1998, pp. 61-65
Objective: Pancreatitis remains the major complication of endoscopic r
etrograde cholangiopancreatography (ERCP). Uncontrolled data suggest a
lower incidence of pancreatitis in patients with a history of iodine
sensitivity when given pretreatment with corticosteroids. We conducted
a clinical trial to assess the efficacy of a commonly prescribed cort
icosteroid, methylprednisolone, to prevent ERCP-induced pancreatitis.
Methods: Patients were entered into a randomized, multicenter, double-
blind, placebo-controlled study of intravenous methylprednisolone (125
mg) versus a saline placebo immediately before the ERCP. All patients
were evaluated for early and late complications. Results: Two hundred
eighty-six patients were randomized. Thirty-one randomized patients w
ere excluded for technical reasons at the time of ERCP. Overall, the i
ncidence of pancreatitis was 16 of 129 (12.4%, 95% CI: 6.7-18.1%) in t
he methylprednisolone group and 11 of 126 (8.7%, 95% CI: 4.4-15.1%) in
the placebo group, which was not significantly different (p = 0.34).
Although there was a higher rate of sphincterotomy performed in the me
thylprednisolone group compared to the control group (31.8% vs 16.8%,
p = 0.005), the incidence of pancreatitis was not different when patie
nts undergoing sphincterotomy were analyzed separately (13.6% in the m
ethylprednisolone group and 9.6% in the placebo group, p = 0.50). Ther
e was no significant difference between the two groups for those with
ERCP-induced pancreatitis in hospital length of stay (p = 0.22), days
of parenteral analgesia (p = 0.09), or days of parenteral nutrition (p
= 0.15). Conclusion: Intravenous methylprednisolone is not beneficial
in preventing ERCP-induced pancreatitis. (C) 1998 by Am. Cell. of Gas
troenterology.